AZD3463 is an investigational anti-cancer agent primarily explored for its potential in treating neuroblastoma and other solid tumors. It functions as an ALK (anaplastic lymphoma kinase) inhibitor, targeting tumor cells with ALK gene alterations that drive uncontrolled cell growth. By inhibiting ALK activity, AZD3463 helps suppress tumor proliferation and induce cancer cell death. It has shown particular promise in preclinical studies involving ALK-positive neuroblastoma, a common pediatric solid tumor. Its ability to cross the blood-brain barrier also makes it a candidate for treating brain metastases associated with ALK-driven cancers. While still in early research stages, AZD3463 contributes to the development of targeted cancer therapies with improved specificity and reduced side effects compared to conventional chemotherapy.